BMS 986263

Drug Profile

BMS 986263

Alternative Names: BMS986263; ND-L02-s0201

Latest Information Update: 14 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nitto Denko
  • Developer Bristol-Myers Squibb; Nitto Denko
  • Class Antifibrotics; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatic fibrosis
  • Preclinical Liver cirrhosis
  • No development reported Fibrosis

Most Recent Events

  • 13 Feb 2018 Phase-II clinical trials in Hepatic fibrosis in USA (IV) (NCT03420768)
  • 02 Feb 2018 Bristol-Myers Squibb plans a phase II trial for Hepatic Fibrosis in USA , (NCT03420768)
  • 31 Dec 2017 Nitto Denko completes a phase I trial in Hepatic fibrosis in Japan (JapicCTI-152959)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top